Triangle Pharmaceuticals Complete Private Equity Financing

23 June 1996

- Triangle Pharmaceuticals, founded in the USA in 1995 by former staff at the UK company Wellcome before its takeover by Glaxo, has completed an $18.5 million second-round private equity financing. Proceeds will be used to advance programs to develop novel therapeutics for serious viral diseases and cancer. "Since our founding in July 1995, we have built a portfolio of six novel drug candidates which are progressing well through the drug development process," commented David Barry, the firm's chairman and chief executive.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight